Across TCGA pan-cancer cohorts, PTMA Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PTMA data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PTMA Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTMA expression acts as an unfavorable survival marker.

CESC, LUAD, and DLBC are the cancer types where PTMA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	All	0.205	0.745	<.001	36	view →
LUAD	OS	Median	All	0.269	0.813	<.001	24	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
ACC	DFS	Median	II,III,IV	0.226	0.725	.009	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PTMA tumor-vs-normal RNA expression · all PTMA data types